Explore 3 Stock Ideas & Industry Insights Download Free Report

18889881171
Shopping Cart 0
countryflagUS
Login

CVRx Inc

Healthcare US CVRX

5.1USD
0.24(4.94%)

Last update at 2026-06-23T18:31:00Z

Day Range

4.815.30
LowHigh

52 Week Range

4.3011.30
LowHigh

Fundamentals

  • Previous Close 4.86
  • Market Cap190.50M
  • Volume170850
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-50.50900M
  • Revenue TTM56.65M
  • Revenue Per Share TTM2.17
  • Gross Profit TTM 48.34M
  • Diluted EPS TTM-2.04

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -53.32400M -59.91000M -41.05200M -41.31900M -42.98700M
Minority interest - - - - -
Net income -53.30600M -59.96500M -41.19900M -41.42800M -43.07800M
Selling general administrative 88.47M 91.32M 61.60M 50.05M 27.86M
Selling and marketing expenses - - - - -
Gross profit 48.34M 42.96M 33.04M 17.47M 9.40M
Reconciled depreciation 0.76M 0.62M 0.52M 0.41M 0.17M
Ebit - -55.51300M -43.10300M -42.52700M -25.96800M
Ebitda -51.26500M -54.89400M -43.10300M -41.15400M -40.76800M
Depreciation and amortization - 0.62M 0.52M 1.37M -14.80000M
Non operating income net other - - - 1.37M -14.80000M
Operating income -51.26500M -59.49000M -43.10300M -42.52700M -25.96800M
Other operating expenses 107.92M 110.78M 82.40M 65.00M 39.00M
Interest expense 5.83M 4.40M 1.80M 0.17M 2.22M
Tax provision -0.01800M 0.06M 0.14M 0.11M 0.09M
Interest income - - - - -
Net interest income -5.82700M -4.39700M -1.38500M -0.16500M -2.21900M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense 0.02M 0.06M -0.14700M 0.11M 0.09M
Total revenue 56.65M 51.29M 39.30M 22.47M 13.04M
Total operating expenses 99.61M 102.45M 76.14M 60.00M 35.36M
Cost of revenue 8.31M 8.33M 6.26M 5.00M 3.64M
Total other income expense net -2.05900M -0.42000M 2.05M 1.21M -17.01900M
Discontinued operations - - - - -
Net income from continuing ops -53.30600M -59.96500M -42.57200M -41.42800M -43.07800M
Net income applicable to common shares - - - -41.42800M -43.07800M
Preferred stock and other adjustments - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 104.79M 133.41M 115.23M 124.94M 152.55M
Intangible assets - - - - -
Earning assets - - - - -
Other current assets 3.07M 2.50M 2.99M 4.22M 2.58M
Total liab 65.47M 62.36M 39.28M 15.76M 6.59M
Total stockholder equity 39.32M 71.06M 75.95M 109.18M 145.96M
Deferred long term liab - - - - -
Other current liab 9.48M 7.76M 5.98M 6.15M 5.40M
Common stock 0.26M 0.25M 0.21M 0.21M 0.20M
Capital stock 0.26M 0.25M 0.21M 0.21M 0.20M
Retained earnings -590.65200M -537.34600M -477.38100M -436.18200M -394.75400M
Other liab - - - 0.81M 0.68M
Good will - - - - -
Other assets - - - 0.03M 0.03M
Cash 75.71M 105.93M 90.57M 106.19M 142.07M
Cash and equivalents - - - - -
Total current liabilities 13.32M 10.76M 7.86M 8.09M 5.91M
Current deferred revenue - - -0.23100M - -
Net debt -24.91800M -55.50100M -59.95600M -99.10800M -142.07200M
Short term debt - 0.28M 0.23M 0.22M -
Short long term debt - - - - -
Short long term debt total 50.79M 50.43M 30.61M 7.09M -
Other stockholder equity 629.92M 608.35M 553.33M 545.36M 388.16M
Property plant equipment - - - 1.70M 1.43M
Total current assets 101.65M 129.81M 112.09M 122.88M 151.10M
Long term investments - - - - -
Net tangible assets - - - 109.18M 145.96M
Short term investments - - - - -
Net receivables 10.66M 9.27M 7.55M 5.50M 2.56M
Long term debt 49.51M 49.27M 29.22M 6.75M -
Inventory 12.21M 12.11M 10.98M 6.96M 3.88M
Accounts payable 3.83M 2.58M 1.88M 1.72M 0.51M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income -0.20300M -0.20600M -0.20700M -0.20700M -0.19800M
Additional paid in capital - - - - -
Common stock total equity - - - 0.21M 0.20M
Preferred stock total equity - - - - -
Retained earnings total equity - - - -436.18200M -394.75400M
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 0.03M 0.03M 0.03M 0.03M 0.03M
Deferred long term asset charges - - - - -
Non current assets total 3.15M 3.60M 3.14M 2.06M 1.45M
Capital lease obligations 0.99M 1.16M 1.39M 0.12M -
Long term debt total - - - 6.75M -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments - -1.36100M -0.50100M -0.68500M -1.18300M
Change to liabilities - - - 2.08M 2.21M
Total cashflows from investing activities -0.58000M -1.36100M -0.59100M -0.68500M -1.18300M
Net borrowings 0.00000M 20.00M 22.50M 6.72M -21.30000M
Total cash from financing activities 10.52M 55.87M 23.98M 7.49M 111.88M
Change to operating activities - - - -0.76100M 0.21M
Net income -53.30600M -59.96500M -41.19900M -41.42800M -43.07800M
Change in cash -30.22500M 15.36M -15.62500M -35.87800M 82.96M
Begin period cash flow 105.93M 90.57M 106.19M 142.07M 59.11M
End period cash flow 75.71M 105.93M 90.57M 106.19M 142.07M
Total cash from operating activities -40.17000M -39.14400M -39.02100M -42.67700M -27.73200M
Issuance of capital stock 8.97M 32.52M 0.00000M 0.00000M 133.16M
Depreciation 0.76M 0.62M 0.52M 0.41M 0.17M
Other cashflows from investing activities - - - - -
Dividends paid - - - - -
Change to inventory -0.09800M -1.12400M -4.02600M -3.07700M -0.53700M
Change to account receivables -1.39700M -1.71700M -2.04700M -2.94400M -1.27900M
Sale purchase of stock - - - 0.77M -0.00100M
Other cashflows from financing activities 10.52M 3.35M 1.48M 7.31M 0.02M
Change to netincome - - - 3.89M 16.53M
Capital expenditures 0.58M 1.36M 0.59M 0.69M 1.18M
Change receivables - - - -2.94400M -1.27900M
Cash flows other operating - - - -1.63400M -1.98000M
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - -35.86900M 82.97M
Change in working capital 1.00M 0.95M -4.80500M -5.57300M -1.58200M
Stock based compensation 11.05M 19.05M 6.30M 3.89M 1.91M
Other non cash items 0.33M 0.20M 0.16M 0.03M 0.23M
Free cash flow -40.75000M -40.50500M -39.61200M -43.36200M -28.91500M

Peer Comparison

Sector: Healthcare Industry: Medical Devices

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
CVRX
CVRx Inc		 0.24 4.94% 5.10 - - 3.36 4.84 2.92 -1.3142
ABT
Abbott Laboratories		 2.35 2.67% 90.17 25.97 17.24 3.57 3.20 3.81 16.75
SYK
Stryker Corporation		 3.72 1.22% 308.41 44.07 24.94 5.51 6.12 6.05 25.73
MDT
Medtronic PLC		 1.07 1.35% 80.34 26.60 15.87 3.35 2.08 3.90 14.12
BSX
Boston Scientific Corp		 0.91 2.04% 45.23 31.49 17.24 4.41 3.65 4.88 19.19

Reports Covered

Stock Research & News

View All

Profile

CVRx, Inc., a commercial-stage medical device company, engages in developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases in the United States, Germany, and internationally. The company offers Barostim, an implantable device that delivers electrical pulses to baroreceptors located in the wall of the carotid artery to counteract decreased baroreceptor signaling, and provides baroreflex activation therapy, which links the cardiovascular system to the autonomic nervous system. It sells its products through direct sales force, sales agents, and independent distributors. The company was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.

CVRx Inc

9201 West Broadway Avenue, Minneapolis, MN, United States, 55445

Key Executives

Name Title Year Born
Mr. Nadim Yared CEO, Pres & Director 1968
Mr. Jared Oasheim Chief Financial Officer 1983
Mr. Paul Verrastro Chief Marketing & Strategy Officer 1963
Mr. Paul Pignato VP of Operations NA
Mr. Craig Palmer Sr. VP of US Sales 1977
Mr. Kevin Hykes President, CEO & Director 1966
Mr. Jared Oasheim Chief Financial Officer 1984
Mr. Paul Pignato Vice President of Operations NA
Ms. Jonelle R. Burnham Vice President & General Counsel 1971
Mr. Craig Palmer Senior Vice President of US Sales 1977

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.